Elezanumab（Cat No.:I042233）is a monoclonal antibody designed to target and inhibit the growth factor receptors of the neurotrophin receptor p75 (p75NTR) and Nerve Growth Factor (NGF). This approach is aimed at treating chronic pain, particularly in conditions like osteoarthritis, by blocking the signaling pathways involved in pain perception. Elezanumab has shown potential in clinical trials to reduce pain and improve mobility by modulating the activity of these receptors. It is being studied for its role in managing pain in various neurological and musculoskeletal disorders, with ongoing research assessing its safety and effectiveness.
